World leading biotech company CSL has commenced construction of its global headquarters in Parkville, the nation’s premier biomedical precinct, which will further cement Melbourne’s position as a world class research destination
The new purpose-built facility, which will also feature state-of-the-art laboratories, will foster and support collaborations between academic biomedical research and industry, and help the company to commercialise new products.
On completion in 2024, the HQ will accommodate more than 800 CSL employees including early stage research and product development teams, commercial operations, corporate functions and support service.
Invest Victoria has supported this project by working closely with developer PDG and various regulatory authorities to progress development design and approvals.
CSL operates in more than 35 countries and has more than 22,000 employees, including 2,500 in Victoria.
Victoria’s medical technologies and pharmaceuticals industry employs more than 23,000 people and generates more than $12.7 billion in revenue per year.
